about
Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenograftsTowards Quantitative Systems Pharmacology Models of Chemotherapy-Induced Neutropenia.Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice.Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects.Aliskiren displays long-lasting interactions with human renin.Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human studyIncorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.Application of quantitative pharmacology in development of therapeutic monoclonal antibodiesPharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeysPharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy.Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic AmyloidosisInterspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice.Target-mediated disposition model describing the dynamics of IL12 and IFNγ after administration of a mifepristone-inducible adenoviral vector for IL-12 expression in mice.Pharmacokinetics of recombinant bifunctional fusion proteins.Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancerScaling pharmacodynamics from in vitro and preclinical animal studies to humans.Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition.Overview of therapeutic drug monitoring.Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.Population pharmacokinetics of exenatidePrediction of exposure-response relationships to support first-in-human study design.Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry.The Øie-Tozer model of drug distribution and its suitability for drugs with different pharmacokinetic behavior.Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.Challenges and considerations for development of therapeutic proteins in pediatric patients.Small-molecule compounds exhibiting target-mediated drug disposition - A case example of ABT-384.Tools for predicting the PK/PD of therapeutic proteins.
P2860
Q30930928-46E21C19-6944-4FCD-ABC4-13340205FA00Q33688233-59CBCC85-3B6F-42C1-AD5B-A4550F7E5F17Q33729784-641D288D-0302-486B-8D3A-B66FED232B3FQ34028124-40519B87-A60B-449B-BE3D-95B6B1C77EB5Q34029257-E0AB7926-A031-4C18-962F-F9AD47F9E8A4Q34109516-BF1E2989-1551-4205-9538-80CB3CADEEB3Q34187345-278CF67A-C0E7-4E89-839A-B9D6C58F1652Q34204024-E7448329-B951-4C31-9AFF-A5E60E5B78C1Q34293586-D37941A8-C30E-4BB7-AFA7-65AC012BEA26Q34293689-4DADB222-55DC-4332-A973-8ED67ACB0628Q34293733-05B64EEF-FB8B-4040-B8C5-FF1A6D8EFA82Q34576320-99B45165-E372-452C-81B7-14E4F01A1ACEQ35079550-88884C96-ABD0-4016-BB6E-63885F2E7BA1Q35168120-90B5FD0F-235F-432F-9FAF-63F9B33E2119Q35168311-39A64041-FF61-4ECD-851E-DDAD73E08CA3Q35179540-137CF8D7-28D9-4D32-8224-DC7E604E9014Q35223673-8B2A354C-D4E0-43E6-BEC6-B838471E0CC7Q36017372-0472E755-DC31-4F61-80ED-58E6FE83E9C1Q36204764-F9C5F705-FA1B-4268-9EBB-61043FF9C8B5Q36502390-CA530565-EF01-4501-8837-63B77627B9F0Q37033032-D57821EF-0333-42BC-B93B-845723BB1439Q37054801-63CF1B34-6A66-4076-B719-A4489D4B5C69Q37055123-97DF40EB-D50B-44AA-9EDC-50ED4292F21EQ37187003-3D2A7436-1560-44BB-A7D8-A1692843319AQ37361908-0F3FEAB9-6D01-4E2B-ABDF-39097E2DA1B7Q37409151-2C54D898-D62B-4D37-98B4-EFCC094EF02CQ37510861-02EA6D46-849D-4378-9864-5340B0581CFCQ37635011-A42D4F4D-BBB8-4E24-B970-B6DB8A3227C0Q37639905-74908AF8-A10F-4F35-B82D-0C4B2C381A8EQ37802266-D924C421-5586-47DF-9743-87CA9DC28A78Q37893563-D0958CDF-D322-4BA4-A2B5-D1F24CA5367BQ37932558-28B94A52-1C9E-4A98-AF01-9E392D17E7EAQ37976121-9752E9AC-9E77-4215-ABD3-B2CC783B3E1AQ38072598-22BBE9A6-1048-4A9B-8A51-544E1D0F6B33Q38204975-595F3258-F49D-4DE0-AE0E-1DE70742652CQ38289581-196EE3D5-D068-43E9-974D-D16927275B80Q38291356-39A0370B-B6ED-4C9B-BB8A-F7F18A61EE0BQ38364457-FDCBEE03-B6CB-4DDD-905A-BD26DC1170CFQ38452569-C0C629B5-901F-4C76-99B1-5E45185E3ADDQ38455786-54F9C38F-852D-497F-986D-B104A7CE0B38
P2860
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Pharmacologic target-mediated drug disposition.
@en
type
label
Pharmacologic target-mediated drug disposition.
@en
prefLabel
Pharmacologic target-mediated drug disposition.
@en
P356
P1476
Pharmacologic target-mediated drug disposition.
@en
P2093
P304
P356
10.1038/CLPT.1994.134
P407
P577
1994-09-01T00:00:00Z